中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

74 records (took 0.037 seconds)

    Ｓｉｒｔ６의 활성 조절용 조성물
    62.
    发明公开
    Ｓｉｒｔ６의 활성 조절용 조성물 审中-实审
    Sirt6活性调节组合物

    公开(公告)号：KR1020170082372A

    公开(公告)日：2017-07-14

    申请号：KR1020160001678

    申请日：2016-01-06

    Applicant: 한국화학연구원

    Inventor： 김광록 ,  최상운 ,  안진희 ,  이준미

    IPC: A61K31/519 ,  A61K31/4192 ,  A61K31/505

    Abstract: 본발명은 Sirt6 enzyme의활성을증가시키는효과가우수한상기화학식 1로표시되는화합물을유효성분으로포함하는항암, cholesterol 합성억제치료용약학조성물을제공하며, 상기조성물은제2형항암및 cholesterol 합성억제치료하는데유용하게사용될수 있다.

    Abstract translation: 本发明提供了一种胆固醇合成抑制疗法，其包含一种化合物，其是有效增加显示为优良式1作为活性成分的SIRT6酶的活性，2型癌症和胆固醇合成抑制的组合物的抗癌药物组合物 它可以用于治疗。

    신규한 퀴녹살린 유도체 및 이를 이용한 신경전구세포 또는 줄기세포의 신경세포로의 분화 유도용 조성물
    65.
    发明公开
    신규한 퀴녹살린 유도체 및 이를 이용한 신경전구세포 또는 줄기세포의 신경세포로의 분화 유도용 조성물 有权
    新型喹啉衍生物及其组合物，用于诱导神经前体细胞或干细胞分化成神经细胞的差异

    公开(公告)号：KR1020130078095A

    公开(公告)日：2013-07-10

    申请号：KR1020110146860

    申请日：2011-12-30

    Applicant: 한국화학연구원

    Inventor： 안진희 ,  최상운 ,  김광록 ,  강승규 ,  정희정

    IPC: C07D405/12 ,  C07D241/36 ,  A61K31/498 ,  A61P25/00

    Abstract: PURPOSE: A novel quinoxaline derivative is provided to differentiate neural progenitor cells or stem cells into nerve cells, and the differentiated neural progenitor cells into specific cells or oligodendrocytes with high efficiency, and to apply the differentiation-induced neural progenitor cells for treating intractable nervous system diseases. CONSTITUTION: A quinoxaline derivative or a salt thereof is denoted by chemical formula 1. A composition for inducing the differentiation of neural progenitor cells or stem cells into nerve cells contains the quinoxaline derivative or the salt thereof as an active ingredient. The stem cells include embryonic stem cells, embryonic germ cells, adult stem cells, and induced pluripotent stem cells. A method for differentiating the neural progenitor cells or the stem cells comprises the step of culturing the neural progenitor cells or the stem cells with the composition.

    Abstract translation: 目的：提供一种新颖的喹喔啉衍生物，用于将神经祖细胞或干细胞分化成神经细胞，将分化的神经祖细胞高效地分化成特异性细胞或少突胶质细胞，并应用分化诱导的神经祖细胞治疗难治性神经系统 疾病。 构成：喹喔啉衍生物或其盐由化学式1表示。用于诱导神经祖细胞或干细胞分化成神经细胞的组合物含有喹喔啉衍生物或其盐作为活性成分。 干细胞包括胚胎干细胞，胚胎生殖细胞，成体干细胞和诱导多能干细胞。 用于分化神经祖细胞或干细胞的方法包括用组合物培养神经祖细胞或干细胞的步骤。

    신규한 3-인돌리논 유도체 및 이를 포함하는 조성물
    67.
    发明公开
    신규한 3-인돌리논 유도체 및 이를 포함하는 조성물 有权
    新的3-吲哚啉酮衍生物和包含其的组合物

    公开(公告)号：KR1020120065926A

    公开(公告)日：2012-06-21

    申请号：KR1020110086551

    申请日：2011-08-29

    Applicant: 한국화학연구원

    Inventor： 안진희 ,  배명애 ,  최은복

    IPC: C07D209/36 ,  C07D209/24 ,  A61K49/00 ,  G01N33/58

    Abstract: PURPOSE: A composition containing a novel 3-indolinone derivative is provided to selectively stain fluorescence to fat and to be used as a diagnosis reagent. CONSTITUTION: A 3-indolinone derivative is denoted by chemical formula 1 or 2. A composition for fluorescence dyeing contains the derivative or salt thereof as an active ingredient. The concentration of the derivative or salt thereof is 1-100 uM. The composition is used for straining fluorescent to fat and diagnosing organism. A kit for detecting lipid contains the derivative or salt thereof as an active ingredient. A kit for diagnosing metabolic diseases contains the derivatives or salt thereof as an active ingredient.

    Abstract translation: 目的：提供含有新的3-二氢吲哚酮衍生物的组合物，以选择性地将荧光染色成脂肪并用作诊断试剂。 构成：3-二氢吲哚酮衍生物由化学式1或2表示。荧光染色用组合物含有作为活性成分的衍生物或其盐。 其衍生物或盐的浓度为1-100uM。 该组合物用于使荧光变为脂肪并诊断生物体。 用于检测脂质的试剂盒含有其衍生物或其盐作为活性成分。 用于诊断代谢疾病的试剂盒含有作为活性成分的衍生物或其盐。

    신경전구세포 또는 줄기세포의 신경세포로의 분화 유도용 조성물 및 방법
    68.
    发明公开
    신경전구세포 또는 줄기세포의 신경세포로의 분화 유도용 조성물 및 방법 有权
    诱导神经前体细胞或干细胞分化为神经细胞的组合物和方法

    公开(公告)号：KR1020100052758A

    公开(公告)日：2010-05-20

    申请号：KR1020080111603

    申请日：2008-11-11

    Applicant: 한국화학연구원

    Inventor： 김광록 ,  최상운 ,  정희정 ,  안진희 ,  이철해 ,  김성수

    IPC: A61K31/165 ,  A61P21/00

    Abstract: PURPOSE: A composition for inducing differentiation of neural precursor cells or stem cells to neural cells is provided to usefully treat nerve injury diseases. CONSTITUTION: A composition for inducing differentiation of neural precursor cells or stem cells to neural cells contains 10-20 Um of hydroxylamide derivative of chemical formula 1 or salt thereof as an active ingredient. The hydroxyamide derivative is denoted by chemical formula 1a or 1b. The stem cells are embryonic stem cells, adult stem cells, germiparity stem cells, or embryonic tumor stem cell. The neural precursor cells or stem cells are differentiated to neural cells by culturing with the composition.

    Abstract translation: 目的：提供用于诱导神经前体细胞或干细胞向神经细胞分化的组合物，以有效治疗神经损伤疾病。 构成：用于诱导神经前体细胞或干细胞分化为神经细胞的组合物含有10-20Um的化学式1的羟基酰胺衍生物或其盐作为活性成分。 羟基酰胺衍生物由化学式1a或1b表示。 干细胞是胚胎干细胞，成体干细胞，胚胎干细胞或胚胎肿瘤干细胞。 通过用组合物培养将神经前体细胞或干细胞分化成神经细胞。

    베타아미노기를 갖는 1,4-디아제펜 유도체, 이의약학적으로 허용 가능한 염 및 이의 제조 방법
    70.
    发明公开
    베타아미노기를 갖는 1,4-디아제펜 유도체, 이의약학적으로 허용 가능한 염 및 이의 제조 방법 有权
    具有β; -AMINO组的1,4-DIAZEPANE衍生物，药物可接受的盐及其制备方法

    公开(公告)号：KR1020080067391A

    公开(公告)日：2008-07-21

    申请号：KR1020070004576

    申请日：2007-01-16

    Applicant: 영진약품 주식회사 ,  한국화학연구원

    Inventor： 김성수 ,  천혜경 ,  이상달 ,  안진희 ,  김기영 ,  강남숙 ,  강승규 ,  정원훈 ,  김성규 ,  김선영 ,  권재홍 ,  손상권 ,  신민기 ,  하니나

    IPC: C07D243/14 ,  C07D417/12 ,  C07D403/12

    CPC classification number: Y02P20/55

    Abstract: A 1,4-diazepane derivative is provided to inhibit the activity of DPP-IV excellently, thereby being effectively used to treat or prevent diseases such as insuline-dependent and insuline-independent diabetes, arthritis, obesity, osteoporosis and injured glucose resistance. A 1,4-diazepane derivative having a beta-amino group is represented by a formula(1), wherein R1 is a group(1) or a group(2); R2 is H, C1-6 alkyl, C3-6 cycloalkyl, C1-6 haloalkyl, heteroaryl, a group(1), a group(2), a group(3), a group(4), a group(5), a group(6), a group(7), a group(8), or a group(9); R2 is H, C1-6 alkyl, C3-6 cycloalkyl, heteroaryl, C1-6 alkoxy, -OCH2O, -SO2NH3, -OCF3, phenoxy, halogen, -CN, -NO2, -CF3, -CONH2, -COOR^b, -CH2COOR^b, -OCHR^bCOOR^b or -NR^bR^c; each R^b and R^c is independently H, C1-6 alkyl or C3-6 cycloalkyl, aryl, alkylaryl, arylsulfonyl, arylcarbonyl, amino acid derivative or -CH2OCOC(CH3)3; R^d is C1-6 alkyl, trifluoromethyl, a group(1), a group(2), a group(10), a group(11), a group(12), a group(13), pyrazinyl, pyrimidinyl or pyrrolyl; R^e is C1-6 alkyl, C3-6 cycloalkyl, a group(1) or a group(2); R^f is, halogen, NR^bR^c, a group(14), a group(15), a group(16), a group(17), a group(10), heteroaryl, -S-heteroaryl, tetrahydroisoquinoline, thiazolidine, piperidin-4-carboxylic acid or tetrahydropyrimidine; A is CH2, N, O or S; B is H, C1-6 alkyl, C3-6 cycloalkyl, benzyl, CO2R^d, 2-pyridyl or aryl; X is O or S; and n is an integer from 1 to 3. A method for preparing the 1,4-diazepane derivative comprises the steps of: (a) subjecting an amino acid represented by a formula(2) and a diazepane compound represented by a formula(3) to condensation to obtain a compound represented by a formula(4); and (b) deprotecting the compound of the formula(4), wherein BOC is a protecting group, and other substitutents are same as defined above. A pharmaceutical composition comprises an effective amount of the 1,4-diazepane derivative or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

    Abstract translation: 提供1,4-二氮杂环庚烷衍生物，以有效地抑制DPP-IV的活性，从而有效地用于治疗或预防诸如胰岛素依赖性和胰岛素依赖性糖尿病，关节炎，肥胖症，骨质疏松症和受损葡萄糖耐药性的疾病。 具有β-氨基的1,4-二氮杂环庚烷衍生物由式（1）表示，其中R1是基团（1）或基团（2）。 R2是H，C1-6烷基，C3-6环烷基，C1-6卤代烷基，杂芳基，基团（1），基团（2），基团（3），基团（4），基团（5） ，组（6），组（7），组（8）或组（9）; R2是H，C1-6烷基，C3-6环烷基，杂芳基，C1-6烷氧基，-OCH2O，-SO2NH3，-OCF3，苯氧基，卤素，-CN，-NO2，-CF3，-CONH2，-COOR2b ，-CH 2 COOR b，-OCHR 2 bCOOR b或-NR b R c; 每个R b和R c独立地是H，C 1-6烷基或C 3-6环烷基，芳基，烷基芳基，芳基磺酰基，芳基羰基，氨基酸衍生物或-CH 2 OCOC（CH 3）3; R 1是C 1-6烷基，三氟甲基，基团（1），基团（2），基团（10），基团（11），基团（12），基团（13），吡嗪基， 或吡咯基; R 6是C 1-6烷基，C 3-6环烷基，基团（1）或基团（2）; （14），基团（15），基团（16），基团（17），基团（10），杂芳基，-S-杂芳基， 四氢异喹啉，噻唑烷，哌啶-4-羧酸或四氢嘧啶; A是CH 2，N，O或S; B是H，C 1-6烷基，C 3-6环烷基，苄基，CO 2 R 12，2-吡啶基或芳基; X是O或S; n为1〜3的整数。一种1,4-二氮杂环庚烷衍生物的制备方法，其特征在于：（a）使式（2）表示的氨基酸和式（3）表示的二氮杂环丁烷化合物 ）缩合得到由式（4）表示的化合物; 和（b）使式（4）的化合物脱保护，其中BOC是保护基，其它取代基与上述定义相同。 药物组合物包含有效量的1,4-二氮杂环庚烷衍生物或其药学上可接受的盐和药学上可接受的载体。

Patent Agency Ranking